Loading
A phase 1/2 trial of WJ22096 in advanced solid tumours, run by Nanjing Jingao biomidical technology Co. Ltd., now recruiting.
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors is a phase 1/2 interventional study registered as NCT07253116 by Nanjing Jingao biomidical technology Co. Ltd., with 20 participants planned, started 2025-11-20 and due to reach its primary completion in 2028-11-30. Interventions recorded: WJ22096.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/